BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25813536)

  • 21. Preclinical evaluation of 2-amino-2-[11C]methyl-butanoic acid as a potential tumor-imaging agent in a mouse model.
    Suzuki C; Tsuji AB; Kato K; Sudo H; Zhang MR; Saga T
    Nucl Med Commun; 2015 Nov; 36(11):1107-12. PubMed ID: 26259115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of ¹⁸F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging.
    Chiotellis A; Mu L; Müller A; Selivanova SV; Keller C; Schibli R; Krämer SD; Ametamey SM
    Eur J Med Chem; 2013; 70():768-80. PubMed ID: 24239624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line.
    Schaider H; Haberkorn U; Berger MR; Oberdorfer F; Morr I; van Kaick G
    Eur J Nucl Med; 1996 Jan; 23(1):55-60. PubMed ID: 8586103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
    Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
    Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
    Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
    World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and preliminary biological evaluation of O-2((2-[(18)F]fluoroethyl)methylamino)ethyltyrosine ([(18)F]FEMAET) as a potential cationic amino acid PET tracer for tumor imaging.
    Chiotellis A; Müller A; Weyermann K; Leutwiler DS; Schibli R; Ametamey SM; Krämer SD; Mu L
    Amino Acids; 2014 Aug; 46(8):1947-59. PubMed ID: 24802247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific PET imaging of xC- transporter activity using a ¹⁸F-labeled glutamate derivative reveals a dominant pathway in tumor metabolism.
    Koglin N; Mueller A; Berndt M; Schmitt-Willich H; Toschi L; Stephens AW; Gekeler V; Friebe M; Dinkelborg LM
    Clin Cancer Res; 2011 Sep; 17(18):6000-11. PubMed ID: 21750203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
    Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
    Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
    Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
    Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
    Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
    Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts.
    Tsuji AB; Sogawa C; Sugyo A; Sudo H; Toyohara J; Koizumi M; Abe M; Hino O; Harada YN; Furukawa T; Suzuki K; Saga T
    Nucl Med Biol; 2009 May; 36(4):379-88. PubMed ID: 19423005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
    J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of [18F]FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation.
    Bruechner K; Bergmann R; Santiago A; Mosch B; Yaromina A; Hessel F; Hofheinz F; van den Hoff J; Baumann M; Beuthien-Baumann B
    Int J Radiat Biol; 2009 Sep; 85(9):772-80. PubMed ID: 19657862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy.
    Norregaard K; Jørgensen JT; Simón M; Melander F; Kristensen LK; Bendix PM; Andresen TL; Oddershede LB; Kjaer A
    PLoS One; 2017; 12(5):e0177997. PubMed ID: 28542311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucose metabolism gene expression patterns and tumor uptake of ¹⁸F-fluorodeoxyglucose after radiation treatment.
    Wilson GD; Thibodeau BJ; Fortier LE; Pruetz BL; Galoforo S; Baschnagel AM; Chunta J; Oliver Wong CY; Yan D; Marples B; Huang J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):620-7. PubMed ID: 25304950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors.
    Goggi JL; Bejot R; Moonshi SS; Bhakoo KK
    J Nucl Med; 2013 Sep; 54(9):1630-6. PubMed ID: 23907757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.